Olgotrelvir (sodium)

Olgotrelvir (STI-1558) sodium is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L) . Olgotrelvir sodium is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells[1][2].

Product Specifications

CAS Number

[2763596-72-9]

Product Name Alternative

STI-1558 (sodium)

UNSPSC

12352005

Target

Cathepsin; SARS-CoV; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/olgotrelvir-sodium.html

Purity

95.0

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(NCC1)[C@@H]1C[C@@H](C(O)S(=O)(O[Na])=O)NC([C@H](CC(C)C)NC(C2=CC3=CC=CC=C3N2)=O)=O

Molecular Formula

C22H29N4NaO7S

Molecular Weight

516.54

References & Citations

[1]Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19.|[2]Mao L, et al. Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19. Med. 2024 Feb 9;5 (2) :169-171.